Results of a retrospective study raise concern that ureteroscopy may adversely affect erectile function.
In these videos, high-volume stone surgeons demonstrate novel approaches to classification, visualization, and treatment of stones.
Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.
Other products discussed include an updated prostate tissue ablation device, a contrast agent for voiding ultrasonography, a bladder cancer test and more.
Despite the excruciating nature of kidney stones, many people can't manage to lower their risk by simply drinking more liquid. Now, a new study finds that one potential tool—a water bottle with a built-in consumption sensor and smartphone link—accurately tracks how much people drink.
Results of a study analyzing global trends in mortality attributable to urolithiasis show that the rate declined over a recent 20-year period.
Other pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.
Whether or not medical expulsive therapy (MET) is a sound recommendation for patients with kidney or ureteral stones is a matter of debate.
Patients undergoing ureteroscopy while remaining on anticoagulant therapy may be at increased risk for bleeding complications, including significant bleeding events and unplanned returns to the operating room, according to a retrospective study
Results from bench studies favor a new open-faced stone retrieval device (Dakota, Boston Scientific) for having greater versatility, efficacy, and durability compared with a competing product, and the in vitro performance of the new instrument is consistent with early clinical experience, says Roger L. Sur, MD.